JP2017536421A - 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物 - Google Patents

片頭痛及び疼痛に関連する状態を処置するための方法及び組成物 Download PDF

Info

Publication number
JP2017536421A
JP2017536421A JP2017547930A JP2017547930A JP2017536421A JP 2017536421 A JP2017536421 A JP 2017536421A JP 2017547930 A JP2017547930 A JP 2017547930A JP 2017547930 A JP2017547930 A JP 2017547930A JP 2017536421 A JP2017536421 A JP 2017536421A
Authority
JP
Japan
Prior art keywords
composition
migraine
pain
ketoprofen
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017547930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536421A5 (enExample
Inventor
フランガキス，クリスト，ジェイ．
バウアー，ウィリアム
リートケ，ウォルフガング
Original Assignee
アケリオス セラピューティクス，インコーポレーテッド
アケリオス セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アケリオス セラピューティクス，インコーポレーテッド, アケリオス セラピューティクス，インコーポレーテッド filed Critical アケリオス セラピューティクス，インコーポレーテッド
Publication of JP2017536421A publication Critical patent/JP2017536421A/ja
Publication of JP2017536421A5 publication Critical patent/JP2017536421A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2017547930A 2014-12-01 2015-12-01 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物 Pending JP2017536421A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085943P 2014-12-01 2014-12-01
US62/085,943 2014-12-01
PCT/US2015/063220 WO2016089893A1 (en) 2014-12-01 2015-12-01 Methods and compositions for treating migraine and conditions associated with pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020001791A Division JP2020073563A (ja) 2014-12-01 2020-01-09 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2017536421A true JP2017536421A (ja) 2017-12-07
JP2017536421A5 JP2017536421A5 (enExample) 2019-01-17

Family

ID=56092337

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017547930A Pending JP2017536421A (ja) 2014-12-01 2015-12-01 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物
JP2020001791A Pending JP2020073563A (ja) 2014-12-01 2020-01-09 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020001791A Pending JP2020073563A (ja) 2014-12-01 2020-01-09 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物

Country Status (6)

Country Link
US (3) US20170266106A1 (enExample)
EP (1) EP3226972A4 (enExample)
JP (2) JP2017536421A (enExample)
CN (1) CN107614061A (enExample)
CA (1) CA3006962A1 (enExample)
WO (1) WO2016089893A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510354A (ja) * 2020-01-10 2023-03-13 ブリオリ バイオテック，エルエルシー ロフェコキシブを含有する外用組成物並びにそれを製造及び使用する方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107789343A (zh) * 2017-11-08 2018-03-13 莫玉艳 一种治疗偏头痛的药物及其制备方法
KR20210124188A (ko) 2018-11-21 2021-10-14 트루모 파마슈티칼스, 인크. 정제된 형태의 로페콕시브, 제조 및 사용 방법
CN113924627A (zh) 2019-02-22 2022-01-11 派尔疗法股份有限公司 用于治疗与偏头痛相关联的症状的系统和方法
CN110432888B (zh) * 2019-08-15 2021-11-23 任鹏宇 一种前庭神经权重信息编码神经元的筛选方法
US10945992B1 (en) * 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
EP3900715A1 (en) * 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Synergistic admixtures of gabapentin and ketoprofen, pharmaceutical compositions and their medical use
KR20230125826A (ko) * 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
CA3229103A1 (en) * 2021-08-16 2023-02-23 Cerecin Inc. Methods for the treatment of migraine and related headache symptoms using tricaprylin
KR20250121336A (ko) * 2022-11-23 2025-08-12 메디콘 파마슈티컬스, 잉크. 중추감작과 관련된 통증의 치료
CN115998724B (zh) * 2023-03-28 2023-06-16 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途
WO2025111079A1 (en) * 2023-11-21 2025-05-30 Medicon Pharmaceuticals, Inc. Isomers of phosphosulindac

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60155111A (ja) * 1983-10-20 1985-08-15 Hisamitsu Pharmaceut Co Inc 安定なケトプロフェン含有外用経皮製剤
US20030119892A1 (en) * 2001-01-05 2003-06-26 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
JP2009506076A (ja) * 2005-08-26 2009-02-12 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 三叉神経疼痛のための薬物送達のための治療手順
JP2013515002A (ja) * 2009-12-18 2013-05-02 アケリオス セラピューティクス，インコーポレーテッド 三叉神経・自律神経性頭痛、片頭痛、および血管症状の治療および予防のための方法および組成物
WO2014052313A1 (en) * 2012-09-27 2014-04-03 Achelios Therapeutics, Inc. Topical ketoprofen composition

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3759980A (en) * 1969-05-26 1973-09-18 Stockton Chemicals Inc Salicylates
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5409704A (en) 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5032582A (en) 1987-02-27 1991-07-16 Liposome Technology, Inc. Method for treating fungal infections with amphotericin B/cholesterol sulfate composition
US4994213A (en) 1988-05-17 1991-02-19 Liposome Technology, Inc. Method of preparing lipid structures
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US5194266A (en) 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
WO1992018104A1 (en) 1991-04-19 1992-10-29 Vestar, Inc. Pharmaceutical formulation and process
HU223343B1 (hu) 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
GR1002207B (en) 1992-08-06 1996-03-27 Johnson & Johnson Consumer Skin care compositions containing imidazoles.
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
WO1996040061A1 (en) 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Method for encapsulating pharmaceutical materials
US6387407B1 (en) 1995-09-29 2002-05-14 L.A.M. Pharmaceutical Corporation Topical drug preparations
US5897880A (en) 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
US5667799A (en) 1995-10-30 1997-09-16 Caldwell; Larry J. Method for treating headache pain with topical local anesthetic compositions
NZ322588A (en) 1995-11-13 1999-01-28 Pitmy Int Nv An administration medium containing nitrous oxide for use in conjunction with analgesics, anti-inflammatories and anti-pyretics to enhance their action
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
US5855907A (en) 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6083996A (en) 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6090368A (en) 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US6139861A (en) 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6642243B1 (en) 1999-07-22 2003-11-04 Ashkan Imanzahrai Migraine medicine and method for treating same
US6896898B1 (en) * 1999-11-19 2005-05-24 Xel Herbaceuticals, Inc. Transdermal delivery system for alkaloids of aconitum species
US20020143047A1 (en) 2001-01-05 2002-10-03 Galer Bradley S. Methods for treating indomethacin responsive headaches
US20030013753A1 (en) 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
WO2004075832A2 (en) 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
US7357950B2 (en) 2003-03-21 2008-04-15 Elizabeth Anne Mazzio Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20050019354A1 (en) 2003-07-23 2005-01-27 Perricone Nicholas V. Topical benfotiamine treatments
JP2007519756A (ja) 2004-01-30 2007-07-19 アンジオテック インターナショナル アーゲー 拘縮を治療するための組成物および方法
JP2007532697A (ja) 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
WO2006122123A2 (en) 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain
US7968540B2 (en) 2005-11-18 2011-06-28 Merck Sharp & Dohme Corp. Spirohydantoin tricyclic CGRP receptor antagonists
US20090312435A1 (en) 2006-08-30 2009-12-17 Auspex Pharmaceuticals, Inc Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
US20080317684A1 (en) 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
CA2668184A1 (en) * 2006-10-31 2008-05-08 Chrono Therapeutics, Inc. Transdermal delivery techniques for drugs, nutraceuticals and other active substances
DK2459183T3 (en) * 2009-07-27 2016-01-18 Nocicepta Llc Methods for the treatment of pain
DK2512479T3 (en) 2009-12-18 2016-06-06 Exodos Life Sciences Ltd Partnership Compositions for the treatment of peripheral vascular disease
AU2010330812B2 (en) 2009-12-18 2016-03-10 Exodos Life Sciences Limited Partnership Methods and compositions for treating inflammation of skin
US9629920B2 (en) 2009-12-18 2017-04-25 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
US9681837B2 (en) 2012-02-20 2017-06-20 Keio University Central sensitization diagnosis device and method for operating same
US8491917B1 (en) * 2012-03-12 2013-07-23 William J. Bender Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head
CA2894696A1 (en) 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
CA3045004A1 (en) 2015-12-16 2017-06-22 Achelios Therapeutics, Inc. Methods and compositions for treating peripheral neuropathy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60155111A (ja) * 1983-10-20 1985-08-15 Hisamitsu Pharmaceut Co Inc 安定なケトプロフェン含有外用経皮製剤
US20030119892A1 (en) * 2001-01-05 2003-06-26 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
JP2009506076A (ja) * 2005-08-26 2009-02-12 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 三叉神経疼痛のための薬物送達のための治療手順
JP2013515002A (ja) * 2009-12-18 2013-05-02 アケリオス セラピューティクス，インコーポレーテッド 三叉神経・自律神経性頭痛、片頭痛、および血管症状の治療および予防のための方法および組成物
WO2014052313A1 (en) * 2012-09-27 2014-04-03 Achelios Therapeutics, Inc. Topical ketoprofen composition

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DER NERVENARZT, vol. 67, no. 8, JPN6014052297, 1996, pages 672 - 681, ISSN: 0004117591 *
DOGAN, MANSUR ET AL., MEDICAL PRINCIPLES AND PRACTICE, vol. 23, no. 6, JPN6019036069, 3 September 2014 (2014-09-03), pages 507 - 510, ISSN: 0004117594 *
FRIEDMAN, MARK H. ET AL., HEART DISEASE: A JOURNAL OF CARDIOVASCULAR MEDICINE, vol. 4, no. 4, JPN6019036071, 2002, pages 212 - 215, ISSN: 0004117596 *
GONCALVES, DANIELA A. ET AL., CURRENT PAIN AND HEADACHE REPORTS, vol. 16, no. 4, JPN6019036068, 2012, pages 359 - 364, ISSN: 0004117593 *
HERSH, E. V. ET AL., JOURNAL OF CLINICAL DENTISTRY, vol. 5, no. 2, JPN6019036070, 1994, pages 54 - 59, ISSN: 0004117595 *
MOORE, R. A. ET AL., BRITISH MEDICAL JOURNAL, vol. 316, no. 7128, JPN6019036067, 31 January 1998 (1998-01-31), pages 333 - 338, ISSN: 0004117592 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510354A (ja) * 2020-01-10 2023-03-13 ブリオリ バイオテック，エルエルシー ロフェコキシブを含有する外用組成物並びにそれを製造及び使用する方法

Also Published As

Publication number Publication date
CA3006962A1 (en) 2016-06-09
EP3226972A1 (en) 2017-10-11
US20170266106A1 (en) 2017-09-21
CN107614061A (zh) 2018-01-19
US20220125712A1 (en) 2022-04-28
WO2016089893A1 (en) 2016-06-09
US11026882B2 (en) 2021-06-08
US20190216720A1 (en) 2019-07-18
JP2020073563A (ja) 2020-05-14
EP3226972A4 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
US11026882B2 (en) Methods and compositions for treating migraine and conditions associated with pain
ES2812532T3 (es) Compuestos, formulaciones y procedimientos para tratar o prevenir la rosácea
AU2016256779B2 (en) Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
ES2386786T3 (es) Método para tratar rubor cutáneo usando agonistas selectivos de receptores alpha-2-adrenérgicos.
ES2654787T3 (es) Formulación farmacéutica disponible por vía oral adecuada para la gestión mejorada de trastornos del movimiento
NO335537B1 (no) Anvendelse av safinamid for fremstilling av medikamenter til behandling av Parkinsons sykdom
BR112020003025A2 (pt) métodos de tratamento de osteoartrite com gel transdérmico de canabidiol
PT2701693T (pt) Tapentadol para prevenção e tratamento de depressão e ansiedade
JP2022169626A (ja) 皮膚疾患の処置のための併用療法
US20070141182A1 (en) Combination of multiple nonteroidal antiinflammatory drugs and muscle relaxants for local treatment of musculoskeletal pain
MX2007006091A (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante.
Dietrich et al. Effects of topical 2% dorzolamide hydrochloride alone and in combination with 0.5% timolol maleate on intraocular pressure in normal feline eyes
TW202014189A (zh) 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物
US9889126B2 (en) Use of naratriptan in the treatment of rosacea
Patel et al. Revolutionizing rosacea treatment with novel drug delivery systems: A review
WO2014049299A1 (fr) Combinaison de laropiprant et de brimonidine pour le traitement de la rosacée
WO2014049297A1 (fr) Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacée
EP3193883A1 (fr) Compositions comprenant un compose de la famille des avermectines et de la doxycycline pour le traitement de la rosacee
FR3100449A1 (fr) Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes
WO2017161432A1 (pt) Uso de uma composição farmacêutica destinada ao tratamento do eritema cutâneo das poiquilodermias
HK1169919B (en) Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200519